Molecular Cancer Diagnostics Market Report 2022: New

0

Dublin, 06 July 2022 (GLOBE NEWSWIRE) — The report “Molecular Diagnostics for Cancer: Market Forecast by Cancer Type, Product and Location with Executive and Consultant Guides and Customization” has been added to from ResearchAndMarkets.com offer.

Main topics covered:

1 Molecular Dx Oncology Market- Strategic Situation Analysis with Impact of COVID-19 Pandemic

2 Guide for Executives, Marketing, Sales and Business Development Staff

3 Guide for Management Advisors and Investment Advisors

4 Introduction and market definition

5 Market Overview
5.1 Market Participants
5.1.1 University research laboratory
5.1.2 Diagnostic test developer
5.1.3 Genomic Instrumentation Provider
5.1.4 Supplier of cell separation and visualization instruments.
5.1.5 Pharmaceutical/Reagent Supplier
5.1.6 Independent test laboratory
5.1.7 National/regional public laboratory
5.1.8 Hospital laboratory
5.1.9 Medical laboratory
5.1.10 Audit bodies
5.1.11 Certification body
5.2 Market Segments
5.2.1 Traditional market segmentation
5.2.2 Focus and segmentation of the laboratory
5.3 Industry structure
5.3.1 Share of hospital tests
5.3.2 Economies of scale
5.3.3 Laboratories in medical practices
5.3.4 Doctors and POCT

6 market trends
6.1 Factors promoting growth
6.1.1 New diagnostics create new markets
6.1.2 New roles for diagnostics
6.1.3 Longevity and results
6.1.4 Expanding the pharmaceutical toolbox
6.1.5 Regulatory withdrawal
6.2 Factors limiting growth
6.2.1 Falling prices
6.2.2 Cost reduction
6.2.3 COVID pandemic
6.2.4 Well-being has a downside
6.3 Instrumentation and Automation
6.3.1 Key Market Share Instruments
6.3.2 Bioinformatics plays a role
6.4 Development of diagnostic technology
6.4.1 Next Generation Sequencing
6.4.2 Changing role of diagnostics
6.4.3 Multiplexing and Foundation One
6.4.4 Pharmacogenomic technology
6.4.5 Whole genome sequencing
6.4.6 Gene editing and gene therapy

7 Recent developments in molecular diagnostics

8 Major MDx Company Profiles

9 The Global Cancer MDx Market
9.1 Cancer MDx – Global Market Overview by Country
9.2 Global Market by Cancer Type – Overview
9.3 Global Market by Product Type – Overview
9.4 Global Market by Location – Overview

10. Global Market by Cancer Type
10.1 MDx Breast Cancer
10.2 MDx Colorectal Cancer
10.3 MDx Cervical cancer
10.4 MDx Lung cancer
10.5 MDx Prostate
10.6 MDx Melanoma Cancer
10.7 MDx Blood
10.8 MDx Companion Dx Development
10.9 MDx Other cancers

11. Global Market by Product Type
11.1 MDx instruments
11.2 MDx reagents
11.3 MDx Software and Services

12. Global Market by Location
12.1 MDx Clinical Laboratory
12.2 MDx Pharmaceutical
12.3 MDx Search

13 Cancer treatment and trials
13.1 FDA Cancer Drug Approvals by Year
13.2 Clinical trials started from 2010 to 2016
13.3 Prevalence of cancer treatments – 2015

Companies cited

  • 10x Genomics, Inc.
  • Abbott Diagnosis
  • AccuraGen Inc.
  • Adaptive biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc.
  • Agilent
  • Anchor Dx
  • ANGLE SA
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bioreference laboratories
  • Bio-Techne
  • Biochip genetics
  • Biocartis
  • Biocept, Inc.
  • Biodésix inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd.
  • bioMérieux Diagnostics
  • Bioneer Company
  • Bioview
  • bolidique
  • Boreal genomics
  • Bristol Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax lifetime
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogenic
  • Clinical genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnoloix LLC
  • Diasorin SpA
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics S.A.
  • Eurofins Scientific
  • Diagnosis of exosomes
  • Exosome Science
  • Tissue Genomics
  • Fluidigm Corp.
  • Fluxion Biosciences
  • Basic medicine
  • Freenome
  • Diagnosis Wako FUJIFILM
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co. Ltd.
  • Genomic health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardian of health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Discovery of Horizon
  • Molecular diagnosis HTG
  • iCellate
  • Illuminated
  • Incell Dx
  • Inivata
  • Integrated diagnostics
  • Invivogenic
  • invivoscribe
  • Janssen Diagnosis
  • MDNA Life Sciences, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • scientific miR
  • Molecular MD
  • MaCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New oncology
  • Novogene Bioinformatics Technology Co. Ltd.
  • Oncocyte
  • OncoDNA
  • Orthoclinic diagnosis
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnosis
  • Custom
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen GmbH
  • Rarecell SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screen cell
  • Meaning Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon biosystems
  • Simfo GmbH
  • Singlera Genomics Inc.
  • Singulomic
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Earlier detection
  • All medical
  • Trovagene
  • Volition
  • Vortex Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/uvsg7w


        
Share.

Comments are closed.